Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-07-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于增补非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the addition of a non-independent director to the company's board. It includes details about the nomination, qualifications, and background of the proposed director, as well as compliance with relevant laws and company bylaws. There is no financial data, audit information, or report content. The document is clearly about board/management changes, specifically the nomination and addition of a board member. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on this announcement, not a report or presentation.
2025-07-23 Chinese
金陵药业股份有限公司关于变更注册资本暨修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding changes in registered capital and amendments to the company's Articles of Association. It details the board meeting resolution to repurchase and cancel restricted shares, resulting in a reduction of total share capital and registered capital. It also outlines specific amendments to the Articles of Association reflecting these changes. The document is a formal announcement of capital change and related governance document revision, not a full financial report or detailed management discussion. It fits the category of Share Issue/Capital Change announcements, as it concerns changes in share capital and company capital structure.
2025-07-23 Chinese
金陵药业股份有限公司第九届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 19th meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes voting results, descriptions of agenda items such as stock incentive plan adjustments, capital changes, and nomination of a new non-independent director. It also references that some matters will be submitted to the shareholders' meeting for approval. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or legal proceeding update. The content focuses on board decisions and management changes, including director nominations and amendments to company bylaws. Therefore, it fits best under Board/Management Information (MANG). The document length is 2290 characters, which is consistent with a detailed board meeting resolution announcement rather than a full report.
2025-07-23 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the use of idle raised funds for cash management by Jinling Pharmaceutical Co., Ltd. It details the amounts, products, dates, yields, and risk control measures related to the company's cash management activities using idle raised funds. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about the company's financing and cash management activities, specifically about the use of raised funds for cash management. The document is longer than 5,000 characters and contains detailed financial data about cash management products and their status. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital usage related to raised funds management.
2025-07-04 Chinese
金陵药业股份有限公司2024年度分红派息实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2024 annual dividend distribution plan approved at the 2024 Annual General Meeting held on June 27, 2025. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. The document does not contain financial statements or detailed financial performance data but focuses on dividend payment details and shareholder information. The document length is 1908 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2025-07-01 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It includes specifics on amounts invested, types of financial products, dates, expected and actual yields, risk assessments, and compliance with regulatory requirements. The document is not a financial report like an annual or interim report, nor is it a certification or a brief announcement of a report. It is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds for cash management, which fits the category of Capital/Financing Update (CAP). The document length is 6779 characters, which is substantial and contains detailed financial data related to capital management but does not constitute a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2025-06-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.